Reduced protein levels of the non-canonical Wnt ligand, Wnt5a, is observed in 45–75% of breast cancer patients and is associated with poor prognosis including early relapse and reduced disease free-survival. The gene discussed is WNT5A; the disease is breast carcinoma.